Financial Performance - In 2023, the company achieved operating revenue of RMB 956.26 million, a decrease of 17.99% compared to the previous year[6]. - The net profit attributable to shareholders was RMB 112.54 million, an increase of 628.78% year-on-year[6]. - The decline in revenue was primarily due to the implementation of the national volume-based procurement policy affecting the sales prices of orthopedic products[6]. - The company fully recognized goodwill impairment of RMB 197.99 million from the acquisition of Aideer in the previous year, contributing to the significant profit increase in 2023[6]. - The report indicates that the overall operating performance showed substantial changes compared to the same period last year[6]. - The company's operating revenue for 2023 was ¥956,259,537.45, a decrease of 17.99% compared to ¥1,166,042,082.06 in 2022[23]. - Net profit attributable to shareholders was ¥112,537,303.89, a significant increase of 628.78% from a loss of ¥21,282,494.18 in 2022[23]. - The net profit after deducting non-recurring gains and losses was ¥61,648,763.58, up 327.50% from a loss of ¥27,098,445.37 in 2022[23]. - Cash flow from operating activities was ¥274,260,691.58, representing a 15.84% increase from ¥236,756,963.51 in 2022[23]. - Basic and diluted earnings per share were both ¥0.1570, a 630.41% increase from a loss of ¥0.0296 in 2022[23]. - Total assets at the end of 2023 were ¥3,354,004,114.33, a decrease of 1.70% from ¥3,412,148,611.26 at the end of 2022[23]. - Net assets attributable to shareholders increased by 4.39% to ¥2,859,842,987.33 from ¥2,739,569,604.96 in 2022[23]. - The company reported a quarterly revenue of ¥294,401,832.83 in Q1 2023, which decreased to ¥213,839,891.49 in Q3 2023[26]. - The company experienced a net profit of ¥74,900,497.03 in Q1 2023, which turned into a loss of ¥16,629,549.62 in Q4 2023[26]. - In 2023, the company reported a total profit of 50,888,540.31, a significant increase from 5,815,951.19 in 2022, marking a year-over-year growth of approximately 775.5%[31]. - The company received government subsidies amounting to 23,359,830.49 in 2023, compared to 22,158,373.72 in 2022, reflecting a growth of about 5.4%[31]. Business Operations and Strategy - The company plans to continue monitoring the impact of procurement policies on its business operations and adjust strategies accordingly[7]. - The company is undergoing changes in accounting policies due to new regulations effective from January 1, 2022, impacting financial reporting[24]. - The company is committed to continuous development in minimally invasive orthopedic medical devices, covering multiple product lines including spinal and trauma products[35]. - The company is navigating regulatory challenges and opportunities presented by recent healthcare reforms, which are reshaping the competitive landscape in the orthopedic medical device sector[36]. - The company plans to enhance its product innovation in orthopedics, focusing on new materials and technologies, while also expanding its business lines to mitigate the negative impacts of procurement policies[42]. - The company is actively developing a diversified medical device distribution service platform to improve its market share and influence in the medical device sales sector[48]. - The company aims to implement a "one invoice system" sales model targeting large hospitals, in line with national medical reform policies[48]. - The company is focusing on innovation in orthopedic products and expanding its international market presence[62]. - The company is implementing cost control measures to enhance profitability, including reducing labor costs and optimizing production processes[62]. - The company is expanding its product specifications to meet market demands, enhancing competitiveness in the orthopedic and neurosurgical product lines[92]. - The company plans to pursue capital expansion strategies through acquisitions and investments in related medical device companies, particularly in the minimally invasive orthopedic field[135]. - The company will enhance its multi-brand strategy by integrating existing sales channels and strengthening collaboration across product lines, aiming to establish a diverse sales network targeting hospitals[136]. - The company plans to accelerate the internationalization strategy, focusing on the PKP/PVP and Elliquence product lines, with dedicated management roles for foreign trade development in various countries[137]. Market and Industry Trends - The orthopedic implant medical device industry is experiencing rapid growth, with domestic companies benefiting from market expansion and import substitution[36]. - The average price reduction in orthopedic trauma medical consumables during centralized procurement reached 88.65%, significantly impacting industry expectations[37]. - The average price drop for selected orthopedic spinal consumables in centralized procurement was 84%, effective from January 2023[39]. - The national centralized procurement for high-value medical consumables, including artificial crystals and sports medicine supplies, resulted in an average price drop of 74% for sports medicine consumables[40]. - The implementation of bulk procurement policies in the orthopedic consumables sector is expected to significantly reduce patient financial burdens and standardize medical practices, leading to the gradual elimination of smaller, less innovative companies[41]. - The medical device industry is facing challenges due to policies aimed at controlling medical insurance costs, which may limit the growth of medical device expenses in healthcare institutions[130]. - The implementation of volume-based procurement policies is expected to increase pressure on pharmaceutical companies while also improving the quality and competitiveness of the medical industry[132]. - Increased competition in the orthopedic market is anticipated, necessitating timely product innovation to maintain profit margins[146]. Research and Development - R&D investment totaled 60.35 million yuan, a decrease of 8.30 million yuan or 12.09% year-on-year, with R&D expenditure accounting for 6.31% of current revenue, an increase of 0.42 percentage points[69]. - The company authorized 37 patents during the reporting period, including 5 invention patents, emphasizing its commitment to intellectual property management[69]. - The number of R&D personnel increased to 104 in 2023, a rise of 25.30% compared to 83 in 2022[93]. - The proportion of R&D personnel with master's degrees increased by 180.00%, from 5 in 2022 to 14 in 2023[93]. - The company is focusing on optimizing its surgical instrument packages based on clinical feedback, which is expected to improve operational efficiency[93]. - The company aims to strengthen its research and development capabilities, focusing on minimally invasive orthopedic surgical products to maintain a competitive edge in the market[134]. Acquisitions and Investments - The company has successfully integrated its product lines and sales channels following the acquisition of Aideer, optimizing its offerings in orthopedic implants and surgical instruments[46]. - The acquisition of Elliquence, LLC has allowed the company to expand into new business areas, particularly in surgical energy platforms and high-value consumables, enhancing its market presence[47]. - The company acquired a 56% stake in Jienuo Medical, enhancing its market competitiveness and operational efficiency in the medical sterilization service sector[50]. - The company completed the acquisition of 100% equity in Elliquence, LLC for approximately $77,152,000 (about ¥49,500 million) as part of its internationalization strategy[1]. - The company completed the acquisition of 100% equity in Jiangsu Aidi Medical Technology Co., Ltd., enhancing its market position[120]. - The registered capital of Jiangsu Aidi was increased from 60 million yuan to 110 million yuan, reflecting the company's commitment to growth[121]. - The company invested 15 million yuan in the Shanghai Hongsheng Houde Private Equity Investment Fund and 10 million yuan in Dongzhi Medical, among other investments, to enhance its industry presence[72]. Governance and Compliance - The financial report was confirmed to be accurate and complete by the board of directors and management, with no significant discrepancies noted[4]. - The company has established independent financial, operational, and personnel systems, ensuring no interference from existing shareholders[183]. - The company has implemented information disclosure management systems to ensure transparency and timely communication with stakeholders[170]. - The company respects and protects the rights of all stakeholders, promoting sustainable and healthy development[171]. - The company has conducted 1 annual and 1 extraordinary shareholders' meeting during the reporting period, ensuring compliance with legal requirements[163]. - The company maintains strict compliance with the "Investor Relations Management System" to ensure effective communication with investors[172]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[168]. Future Outlook - Future outlook includes a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[190]. - The company is investing 368.4 million in research and development for new technologies and products in the upcoming year[191]. - Market expansion efforts are focused on increasing presence in Southeast Asia, with a target of capturing an additional 10% market share by 2025[192]. - New product lines are expected to launch in Q3 2024, which are anticipated to contribute an additional 5% to overall revenue[194]. - The company has set a goal to reduce operational costs by 10% through efficiency improvements and technology integration[197]. - The company aims to enhance customer engagement through digital platforms, expecting a 30% increase in online interactions[200]. - Future guidance indicates a focus on sustainability initiatives, with a commitment to reduce carbon emissions by 20% over the next five years[200].

2023 年度独立董事述职报告（鲁旭波） 2023 年度，本人作为上海凯利泰医疗科技股份有限公司（以下简称"公司"） 的独立董事，在职期间本人严格按照《上市公司独立董事规则》《上市公司独立 董事履职指引》《深圳证券交易所创业板股票上市规则》《上市公司自律监管指引 第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》及《公司 章程》等规定，在 2023 年度的工作中，诚实、勤勉、独立的履行职责，积极出 席公司 2023 年度召开的相关会议，与公司管理层保持沟通交流，认真阅读会议 相关材料，认真审议董事会上的各项议案，对公司重大事项发表了独立意见，切 实维护了公司和股东尤其是中小股东的利益，充分发挥了独立董事的作用。现将 2023 年度本人履行独立董事职责工作情况汇报如下： 一、 独立董事的基本情况介绍 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。本人履历如下： 鲁旭波先生，1980 年 3 月出生，中国国籍，无境外居留权，本科学历。2005 年 12 月至 2016 年 6 月任职于浙江康盛股份有限公司，历任董秘助理、证券事务 代表、投资部经 ...

上海凯利泰医疗科技股份有限公司 未来三年（2024-2026 年）股东分红回报规划 为完善和健全上海凯利泰医疗科技股份有限公司（以下简称"公司"）利润 分配政策，建立健全科学、持续、稳定的分红决策和监督机制，增加利润分配决 策的透明度和可操作性，积极回报投资者、充分保障投资者的合法权益，引导投 资者树立长期投资和理性投资理念。根据中国证监会《关于进一步落实上市公司 现金分红有关事项的通知》（证监发[2012]37 号）、《上市公司监管指引第 3 号— —上市公司现金分红（2023 年修订）》（中国证券监督管理委员会公告[2023]61 号）和《公司章程》等相关文件、制度的规定，并综合公司未来的经营发展规划、 盈利能力、现金流量状况等因素，制定了《未来三年（2024-2026 年）股东分红 回报规划》（以下简称"本规划"），具体内容如下： 一、 公司制订股东回报规划考虑的因素 公司制定本规划着眼于公司的长远和可持续发展，综合考虑公司的盈利能力、 经营模式、发展阶段、投资资金需求、现金流状况、股东回报、社会资金成本及 外部融资环境等因素，平衡股东的投资回报和公司未来发展的资金需要，建立科 学、稳定、持续的利润分配 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-014 上海凯利泰医疗科技股份有限公司 关于向多家银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司(以下简称"公司")于 2024 年 4 月 18 日召开第五届董事会第十四次会议，审议通过了《关于向多家银行申请综合授信 额度的议案》，本事项尚需提交股东大会审议。现就相关情况公告如下： 根据公司经营发展的需要，为保证公司及公司全资、控股子公司现金流量充 足，公司（含全资子公司和控股子公司）预计向多家合作的商业银行申请总额不 超过人民币 8 亿元的综合授信（最终以各家银行实际审批的授信额度为准），用 于流动资金贷款、开立银行承兑汇票、信用证、商业承兑汇票贴现等，授信期限 为 1 年，授信期限内额度可循环使用。 上述授信总额度不等于公司的实际融资金额，实际借款金额应在授信额度内 以相关银行与公司及公司全资或控股子公司实际发生的贷款金额为准。公司管理 层可根据经营情况增加授信银行范围，调整银行之间的授信额度。 上述银行综合授信事项授权期限自股东大会 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-011 上海凯利泰医疗科技股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、上海凯利泰医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日以邮件方式向公司各监事发出关于召开第五届监事会第十四次会议的通知。 2、公司于 2024 年 4 月 19 日 10 时 30 分以现场结合通讯方式召开监事会。 3、本次监事会会议应出席的监事 3 名，实际出席会议的监事 3 名。 4、会议由周志强先生主持，公司董事会秘书列席本次会议。 2023 年度，公司监事会在董事会和公司各级领导的支持配合下，严格按照 《公司法》《证券法》《公司章程》及《监事会议事规则》等有关规定的要求，认 真履行监督职责，切实维护公司利益和股东权益，对公司的生产经营活动、重大 事项、财务状况以及董事、高级管理人员履行职责情况进行了监督和检查。 表决结果：本议案以 3 票同意、0 票反对、0 票弃权获得通过。本议案尚需 提交公司股东大会审议。 1 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-020 上海凯利泰医疗科技股份有限公司 关于召开2023年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、召开本次会议的基本情况 1、股东大会届次：2023年度股东大会 2、会议召集人：公司董事会 3、会议召开的合法性及合规性：公司第五届董事会第十四次会议审议通过 了《关于提请召开公司2023年度股东大会的议案》，本次股东大会会议的召开符合 有关法律、行政法规、部门规章、规范性文件和公司章程等规定。 4、会议召开日期和时间： （1）现场会议时间为：2024年5月22日（星期三）14时50分 （2）网络投票时间：2024年5月22日。其中，通过深圳证券交易所交易系统 进行网络投票的时间为：2024年5月22日上午9:15—9:25、9:30—11:30，下午 13:00—15:00；通过深圳证券交易所互联网投票系统投票的时间为：2024年5月22 日上午9:15至下午15:00。 5、会议召开方式： 本次股东大会采用现场投票、网络投票相结合的方式召开。公司将通过深圳 证券交易所交 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-015 上海凯利泰医疗科技股份有限公司 关于提请股东大会授权董事会办理以简易程序 向特定对象发行股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 上海凯利泰医疗科技股份有限公司(以下简称"公司")于 2024 年 4 月 18 日召开第 五届董事会第十四次会议，于 2024 年 4 月 19 日召开第五届监事会第十四次会议，审议 通过了《关于提请股东大会授权董事会办理以简易程序向特定对象发行股票的议案》， 现将相关事宜公告如下。 根据《上市公司证券发行注册管理办法》、《深圳证券交易所上市公司证券发行上市 审核规则》、《深圳证券交易所上市公司证券发行与承销业务实施细则》等相关规定，公 司董事会提请股东大会授权董事会办理 2024 年度以简易程序向特定对象发行融资总额 不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权期限为 2023 年年度 股东大会通过之日起至 2024 年年度股东大会召开之日止。具体情况如下： 一、具体内容 （一）拟发行证券的种类和数量 发行股票募集资金总 ...

证券代码：300326 证券简称：凯利泰 公告编号：2024-017 上海凯利泰医疗科技股份有限公司 关于向子公司提供借款展期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1、上海凯利泰医疗科技股份有限公司(以下简称"公司")拟对子公司洁诺医疗管理集 团有限公司(以下简称"洁诺医疗")提供的借款进行展期，双方拟签订《借款合同展期协 议二》，借款总额调整为向子公司提供最高借款余额不超过人民币 9,000 万元，借款期限 延长至2025年6月30日，借款利率不低于中国人民银行同期贷款市场报价利率（LPR）， 具体参考当期银行实际贷款利率情况。洁诺医疗其他股东按出资比例提供相应股权质押 担保。 2、本次借款展期事项已经公司第五届董事会第十四次会议和第五届监事会第十四 次会议审议通过，需提交公司股东大会审议。 3、本次借款展期对象为公司的子公司（公司通过控股子公司上海景正医疗科技有 限公司持有其 56%的股权，并纳入公司合并报表范围），公司对其具有实质的控制和影 响，整体风险处于可控范围之内，不存在损害公司及股东特别是中小股东利益的情形。 一 ...

上海凯利泰医疗科技股份有限公司董事会 关于独立董事独立性情况的专项意见 二〇二四年四月十九日 上海凯利泰医疗科技股份有限公司 董事会 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 (2023 年修订)》以及《公司章程》等规定，就公司在任独立董事郑卫茂、戴雪光、 鲁旭波的独立性情况进行评估并出具如下专项意见： 经核查，独立董事郑卫茂、戴雪光、鲁旭波的任职经历以及签署的相关自查 文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东 公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其 进行独立客观判断的关系，不存在其他影响独立董事独立性的情况，符合《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》中对独立董事独立性的相关要求。 ...

2023 年度总经理工作报告 各位董事： 2023 年度，随着国家及省市联盟常态化、制度化开展高值医用耗材集中带 量采购，骨科关节类、创伤类、脊柱类三大领域均纳入骨科医用耗材集采范围并 陆续落地执行；2023 年 11 月，第四批国家组织高值医用耗材集采正式启动，运 动医学类耗材产品首次纳入集采范围，随着此次集采的尘埃落地，意味着骨科四 大类高值医用耗材基本实现集采全覆盖。 本报告期内，公司全体员工在董事会的领导下，积极应对医疗卫生体制改革 的新变化，顺应骨科集采的新常态，公司坚持贯彻执行公司内生与外延并重的未 来发展战略，结合国内医疗器械市场的发展趋势，持续对主营业务进行调整和优 化,集中优势资源，优化公司资源配置，专注在具有更强竞争优势的领域发展。 本报告期内，为应对高值耗材带量采购政策对公司业务的全面冲击，公司立 足骨科产品创新，根据市场需求进行深度挖掘和创新，结合市场、技术发展趋势 和临床反馈，不断更新迭代现有产线，并积极优化营销网络，持续拓宽产品线和 开拓新的业务领域，公司坚持国际化发展战略，加大海外市场布局，加速国际业 务进程。报告期内公司继续强化成本管控和费用管控，公司通过压缩人力成本、 降低营 ...